menu
    • menu
    [{"orgOrder":0,"company":"Apex Pharmaceuticals, Inc.","sponsor":"Apex Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Apex Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apex Pharmaceuticals, Inc. \/ Apex Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Apex Pharmaceuticals, Inc. \/ Apex Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Apex Pharmaceuticals, Inc.","sponsor":"Apex Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bladogra","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Apex Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apex Pharmaceuticals, Inc. \/ Apex Pharmaceuticals, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Apex Pharmaceuticals, Inc. \/ Apex Pharmaceuticals, Inc."}]

    Find Clinical Drug Pipeline Developments & Deals by Apex Pharmaceuticals, Inc.

    Menu

    Apex Pharmaceuticals, Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apex Pharmaceuticals, Inc.

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Apex Pharmaceuticals, Inc.

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bladogra

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical...

                            Details : Bladogra is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 20, 2020

                            Lead Product(s) : Bladogra

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apex Pharmaceuticals, Inc.

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Apex Pharmaceuticals, Inc.

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elvitegravir

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & ...

                            Details : Elvitegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2015

                            Lead Product(s) : Elvitegravir

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth